Your browser doesn't support javascript.
loading
Customizably designed multibodies neutralize SARS-CoV-2 in a variant-insensitive manner.
Abreu, Cecilia; Ortega, Claudia; Olivero-Deibe, Natalia; Carrión, Federico; Gaete-Argel, Aracelly; Valiente-Echeverría, Fernando; Soto-Rifo, Ricardo; Milan Bonotto, Rafaela; Marcello, Alessandro; Pantano, Sergio.
Afiliación
  • Abreu C; Institut Pasteur de Montevideo, Montevideo, Uruguay.
  • Ortega C; Institut Pasteur de Montevideo, Montevideo, Uruguay.
  • Olivero-Deibe N; Institut Pasteur de Montevideo, Montevideo, Uruguay.
  • Carrión F; Institut Pasteur de Montevideo, Montevideo, Uruguay.
  • Gaete-Argel A; Laboratory of Molecular and Cellular Virology, Virology Program, Institute of Biomedical Sciences, Faculty of Medicine, Universidad de Chile, Santiago, Chile.
  • Valiente-Echeverría F; Millennium Institute on Immunology and Immunotherapy, Santiago, Chile.
  • Soto-Rifo R; Laboratory of Molecular and Cellular Virology, Virology Program, Institute of Biomedical Sciences, Faculty of Medicine, Universidad de Chile, Santiago, Chile.
  • Milan Bonotto R; Millennium Institute on Immunology and Immunotherapy, Santiago, Chile.
  • Marcello A; Laboratory of Molecular and Cellular Virology, Virology Program, Institute of Biomedical Sciences, Faculty of Medicine, Universidad de Chile, Santiago, Chile.
  • Pantano S; Millennium Institute on Immunology and Immunotherapy, Santiago, Chile.
Front Immunol ; 14: 1226880, 2023.
Article en En | MEDLINE | ID: mdl-37638023
ABSTRACT
The COVID-19 pandemic evolves constantly, requiring adaptable solutions to combat emerging SARS-CoV-2 variants. To address this, we created a pentameric scaffold based on a mammalian protein, which can be customized with up to 10 protein binding modules. This molecular scaffold spans roughly 20 nm and can simultaneously neutralize SARS-CoV-2 Spike proteins from one or multiple viral particles. Using only two different modules targeting the Spike's RBD domain, this construct outcompetes human antibodies from vaccinated individuals' serum and blocks in vitro cell attachment and pseudotyped virus entry. Additionally, the multibodies inhibit viral replication at low picomolar concentrations, regardless of the variant. This customizable multibody can be easily produced in procaryote systems, providing a new avenue for therapeutic development and detection devices, and contributing to preparedness against rapidly evolving pathogens.
Asunto(s)
Palabras clave

Texto completo: 1 Banco de datos: MEDLINE Asunto principal: SARS-CoV-2 / COVID-19 Límite: Animals / Humans Idioma: En Revista: Front Immunol Año: 2023 Tipo del documento: Article País de afiliación: Uruguay

Texto completo: 1 Banco de datos: MEDLINE Asunto principal: SARS-CoV-2 / COVID-19 Límite: Animals / Humans Idioma: En Revista: Front Immunol Año: 2023 Tipo del documento: Article País de afiliación: Uruguay